Dihexa dosage: reported doses and schedule
An experimental memory compound with disputed animal research and no established human dose.
Also called: PNB-0408, N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide.
Nootropic peptides · Modified angiotensin IV peptide; proposed HGF/MET modulator · Evidence: Animal studies only.
Typical reported dose: 10 mg under the tongue twice a week
- 10 mg twice weekly: 10 mg under the tongue twice weekly twice weekly, under the tongue. Reported by users, rare report. Studied in: Adults posting self-experiments online; identity and product content unverified. (source)
- Five daily doses, then weekly: 15 mg daily for 5 days, then 20 mg once weekly daily for 5 days, then once weekly, under the tongue. Reported by users, rare report. Studied in: Adults posting self-experiments online; identity and product content unverified. (source)
- 5-10 mg weekly report: 5-10 mg once weekly once weekly, by mouth. Reported by users, rare report. Studied in: Adults posting self-experiments online; identity and product content unverified. (source)
- 20 mg daily, planned breaks: 20 mg daily daily, by mouth. Reported by users, rare report. Studied in: Adults posting self-experiments online; identity and product content unverified. (source)
- 10 mg, then 5 mg: 10 mg every other day for 1 week, then reduced to 5 mg every other day initially; later frequency not restated, by mouth. Reported by users, rare report. Studied in: Adults posting self-experiments online; identity and product content unverified. (source)
- Skin application every 3-5 days: 15-30 mg in a DMSO preparation every 3-5 days every 3-5 days, skin patch. Reported by users, rare report. Studied in: Adults posting self-experiments online; identity and product content unverified. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to Dihexa
- Semax: A Russian nasal peptide with limited human evidence for brain and nerve effects.
- Selank: A Russian nasal anxiety peptide with uncertain long-term benefit and safety.
- PE-22-28: An experimental mood peptide studied in mice, with no human trials found.
- P21: An experimental memory peptide with animal research and no established human dose or safety profile.
- Cerebrolysin: An injectable pig brain mixture with mixed stroke, brain-injury and dementia evidence.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Cellulitis, NHS · NHS · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- Meeting of the Pharmacy Compounding Advisory Committee, FDA · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- TGA strengthens compliance focus on unapproved peptide products as part of evolving risk response, Therapeutic Goods Administration · TGA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- <797> FAQs, United States Pharmacopeia · 2023
- Anaphylaxis, NHS · NHS · 2023
- Drug Product Database: Access the database, Health Canada · Health Canada
- Drugs@FDA Data Files, FDA
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.